| Date | Acquiring pharma company | Acquired biotech company | Amount | Terms / other |
|---|---|---|---|---|
| 2009-12-16 | Silence Therapeutics (UK) | Intradigm (USA) | See details | |
| 2009-12-14 | Qiagen (The Netherlands) | SABiosciences (USA) | US$90 million in cash (€61.8 million) | See details |
| 2009-11-23 | Pfizer (USA) | assets related to stem cell therapies from Axordia (UK - Intercytex's wholly owned subsidiary) | $750,000 | See details |
| 2009-11-18 | Cosmo Pharmaceuticals (Italy) | BioXell (Italy) | CHF 41.3 million (€ 27.4 million) | See details |
| 2009-11-16 | TiGenix (Belgium) | Orthomimetics (UK) | €16 million ($ 23.8 million) | See details |
| 2009-11-12 | Biota (Australia) | antibacterial assets of Prolysis (UK) | Under the terms of the agreement, Biota will acquire the key assets and programs for: - $A10.8 million (£6.4million ) as Biota ordinary shares, of which 60% will be subject to a 12 month escrow period; - the ability to receive up to a 15% share in all milestone and royalties earned on commercialisation with Biota retaining all upfront payments on licensed programs. |
See details |
| 2009-11-05 | Agennix (USA) | GPC Biotech (Germany) | See details | |
| 2009-11-03 | Lonza (Switzerland) | Algonomics (Belgium) | The purchase price was not disclosed. | See details |
| 2009-10-30 | Proximagen Neuroscience (UK) | Cambridge Biotechnology Ltd (UK - Swedish Biovitrum's wholly-owned subsidiary) | Detailed financial terms of the deal are not being disclosed. CBT will be acquired on a cash free/debt free basis and has not generated any third party revenues. |
See details |
| 2009-10-23 | Eurogentec (Belgium) | Anaspec (USA) | undisclosed | See details |
| 2009-10-13 | Lonza (Switzerland) | Simbiosys Bioawares India (India) | Financial details were not disclosed. | See details |
| 2009-10-01 | Sanofi-Aventis (France) | Fovea Pharmaceutical (France) | €370 millions, including an immediate upfront payment and subsequent milestone payments related to the three clinical compounds. |
See details |
| 2009-09-28 | Abbott (USA) | Solvay Pharmaceuticals (Belgium) | €5.2 billion including purchase price of €4.5 billion in cash and additional potential payments of up to €300 million if certain milestones are met between 2011 and 2013. It also includes the assumption of certain liabilities, which Solvay today values at approximately €400 million. |
See details |
| 2009-09-23 | Qiagen (The Netherlands) | DxS Ltd (UK) | US$ 95 million in cash (subject to customary purchase price adjustments), plus up to an additional US$ 35 million if specified commercial and other milestones are met. | See details |
| 2009-09-18 | Evolva (Switzerland) | Arpida (Switzerland) | See details |
